Acceptance of medications for opioid use disorder in recovery housing programs in Missouri
Journal of Substance Abuse Treatment · 2022-07 · 138 · 108747
DOI: 10.1016/j.jsat.2022.108747 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Substance Abuse Treatment, 2022-07. Verfasst von Claire A Wood und 7 weiteren Autor:innen. Beteiligte Einrichtung: University of Missouri - St. Louis, Missouri Institute of Mental Health, United States of America. Electronic address: Claire.Wood@mimh.edu. Hauptthemen laut MEDLINE: Buprenorphine, Opioid-Related Disorders. Die Arbeit wurde bisher 30-mal zitiert (Crossref) und nennt 60 Literaturangaben. Gefördert von: Substance Abuse and Mental Health Services Administration, University of Missouri-St. Louis, Mississippi Department of Mental Health.
Themen: Sucht und Abhängigkeit
Abstract (Originalsprache)
BACKGROUND: Recovery housing plays an important role in supporting individuals in their recovery by building recovery capital and providing stable living environments; however, the extent to which medications for opioid use disorder (MOUD), the gold standard for OUD treatment, are accepted in recovery housing settings is unclear. The purpose of this study, as part of a larger statewide evaluation of Missouri recovery homes, was to identify the extent to which Missouri recovery houses were accepting of methadone, buprenorphine, and naltrexone as well as the extent to which the acceptance of each medication was linked to whether the recovery home encouraged tapering off MOUDs. METHODS: Sixty-four recovery housing managers and/or staff, out of 66 eligible recovery homes in Missouri completed the survey. RESULTS: Results indicated that methadone was the least accepted medication for long-term use followed by buprenorphine and then naltrexone. Recovery houses that had significantly lower overall acceptance of methadone encouraged tapering; however, the overall acceptance for buprenorphine and naltrexone was not significantly related to the encouragement of tapering off MOUDs. CONCLUSION: This work highlights the need to develop reliable instruments to measure and assess MOUD-capable recovery homes and to increase knowledge and acceptance of MOUD within recovery home settings.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- University of Missouri - St. Louis, Missouri Institute of Mental Health, United States of America. Electronic address: Claire.Wood@mimh.edu.
- University of Missouri - St. Louis, Missouri Institute of Mental Health, United States of America.
- Rutgers University - New Brunswick, New Jersey, School of Social Work, United States of America.
- Parents as Teachers National Center, United States of America.
- Missouri Department of Mental Health, Division of Behavioral Health, United States of America.
Förderung
- Substance Abuse and Mental Health Services Administration
- University of Missouri-St. Louis
- Mississippi Department of Mental Health
Zitieren
APA
Wood, C. A., Duello, A., Miles, J., Lohmann, B., Gochez-Kerr, T., Richardson, K., Anderson-Harper, R., & Winograd, R. P. (2022). Acceptance of medications for opioid use disorder in recovery housing programs in Missouri. Journal of Substance Abuse Treatment, 138, 108747. https://doi.org/10.1016/j.jsat.2022.108747
Vancouver
Wood CA, Duello A, Miles J, Lohmann B, Gochez-Kerr T, Richardson K, et al. Acceptance of medications for opioid use disorder in recovery housing programs in Missouri. Journal of Substance Abuse Treatment. 2022;138:108747. doi:10.1016/j.jsat.2022.108747
BibTeX
@article{Wood2022,
author = {Wood, Claire A and Duello, Alex and Miles, Jennifer and Lohmann, Brenna and Gochez-Kerr, Tatiana and Richardson, Kori and Anderson-Harper, Rosie and Winograd, Rachel P},
title = {Acceptance of medications for opioid use disorder in recovery housing programs in Missouri},
journal = {Journal of Substance Abuse Treatment},
year = {2022},
volume = {138},
pages = {108747},
doi = {10.1016/j.jsat.2022.108747}
}
EUVIMED